Skip to main content
Clinical Trials/NCT00319566
NCT00319566
Completed
Phase 3

Heart and Estrogen-Progestin Replacement Study (HERS)

University of California, San Francisco1 site in 1 country2,430 target enrollmentJuly 1992

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Coronary Heart Disease
Sponsor
University of California, San Francisco
Enrollment
2430
Locations
1
Primary Endpoint
Myocardial Infarction
Status
Completed
Last Updated
20 years ago

Overview

Brief Summary

The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.

Detailed Description

A randomized, blinded trial in post menopausal women with cornaornary artery disease to test the hypothesis, among 2340 women who have a uterus, that those randomized to receive estrogen-progestin replacement therapy (Premanrin .625 mg daily plus medroxygrprogesterone acetate 2.5 mg daily) have the same frequency on new CHD events (myocardial infarction and CHD death) as those randomized to placebo.

Registry
clinicaltrials.gov
Start Date
July 1992
End Date
July 2001
Last Updated
20 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • \<75 y.o.
  • uterus present
  • postmenopausal
  • evidence of CHD
  • signed consent

Exclusion Criteria

  • MI, CABG, mechanical revascularization within 6 months
  • serum triglyceride \>300mg/dl
  • used hormone therapy or estrogen vaginal cream in past 3 months
  • history of DVT or pulmonary embolism
  • history of breast cancer or mammogram suggestive of cancer
  • history of endometrial cancer
  • abnormal uterine bleeding
  • pap smear abnormal
  • SGOT more than 1.2 times normal
  • Disease judged to be fatal within 4 yrs

Outcomes

Primary Outcomes

Myocardial Infarction

CHD Death

Secondary Outcomes

  • CABG, revascularization, angina
  • serum lipids
  • quality of life
  • compliance
  • incidence of uterine bleeding and endometrial hyperplasia
  • incidencet and severity of vasomotor and genitourinary symptoms
  • adverse effects
  • thromboembolic events
  • symptomatic gallbladder disease
  • fractures
  • cancer
  • stroke
  • peripheral arterial disease
  • total mortality

Study Sites (1)

Loading locations...

Similar Trials